Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, February 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 7,130 followers.

RT @EEconAES: Cost-utility of denosumab for the treatment of postmenopausal #osteoporosis in Spain @josepdarba http://t.co/Dx8GGIg2kW @Amgen

High #fracture_risk (>75 yrs with fracture or T-score ≤-3.5): #denosumab was cost-saving compared vs alendronate http://t.co/JK0qwj2DWX

High #fracture_risk (>75 yrs with fracture or T-score ≤-3.5): #denosumab was cost-saving compared vs alendronate http://t.co/JK0qwj2DWX

High #fracture_risk (>75 yrs with fracture or T-score ≤-3.5): #denosumab was cost-saving compared vs alendronate http://t.co/JK0qwj2DWX

Cost-utility of denosumab for the treatment of postmenopausal #osteoporosis in Spain @josepdarba http://t.co/Dx8GGIg2kW @Amgen